BR112022023288A2 - Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos - Google Patents

Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos

Info

Publication number
BR112022023288A2
BR112022023288A2 BR112022023288A BR112022023288A BR112022023288A2 BR 112022023288 A2 BR112022023288 A2 BR 112022023288A2 BR 112022023288 A BR112022023288 A BR 112022023288A BR 112022023288 A BR112022023288 A BR 112022023288A BR 112022023288 A2 BR112022023288 A2 BR 112022023288A2
Authority
BR
Brazil
Prior art keywords
methods
polypeptide complexes
activabable
polypeptides
cleavable
Prior art date
Application number
BR112022023288A
Other languages
English (en)
Inventor
Winston William
Seidel-Dugan Cynthia
Hicklin Daniel
Brodkin Heather
Andres Salmeron-Garcia Jose
Steiner Philipp
Original Assignee
Werewolf Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werewolf Therapeutics Inc filed Critical Werewolf Therapeutics Inc
Publication of BR112022023288A2 publication Critical patent/BR112022023288A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

POLIPEPTÍDEOS DE IL-12 ATIVÁVEIS E MÉTODOS DE USO DOS MESMOS. São fornecidos neste documento complexos polipeptídicos de IL-12 e/ou complexos polipeptídicos de IL23 compreendendo IL-12 ou IL-23, um elemento de extensão de meia-vida, um elemento de bloqueio de IL-12 ou IL-23 e um ligante clivável por protease. Também são fornecidas neste documento composições farmacêuticas das mesmas, bem como ácidos nucleicos, vetores de expressão recombinantes, células hospedeiras para produzir tais complexos polipeptídicos. Também são divulgados métodos de utilização dos complexos polipeptídicos no tratamento de doenças, condições e distúrbios.
BR112022023288A 2020-05-19 2021-05-18 Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos BR112022023288A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063027276P 2020-05-19 2020-05-19
PCT/US2021/033014 WO2021236676A1 (en) 2020-05-19 2021-05-18 Activatable il-12 polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022023288A2 true BR112022023288A2 (pt) 2023-01-24

Family

ID=76375661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023288A BR112022023288A2 (pt) 2020-05-19 2021-05-18 Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos

Country Status (11)

Country Link
US (1) US20240043488A1 (pt)
EP (1) EP4153612A1 (pt)
JP (1) JP2023526428A (pt)
KR (1) KR20230012564A (pt)
CN (1) CN116096738A (pt)
AU (1) AU2021276337A1 (pt)
BR (1) BR112022023288A2 (pt)
CA (1) CA3178657A1 (pt)
IL (1) IL298295A (pt)
MX (1) MX2022014411A (pt)
WO (1) WO2021236676A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4004026A4 (en) * 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
CA3211924A1 (en) 2021-03-16 2022-09-22 Sayantan Mitra Masked activatable cytokine constructs and related compositions and methods
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2023196897A1 (en) * 2022-04-07 2023-10-12 Werewolf Therapeutics Inc. Il-12 prodrugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110728A2 (en) 2005-04-12 2006-10-19 The Uab Research Foundation Immunogenic cmv tegument aggregates
US10472816B2 (en) 2017-07-26 2019-11-12 Justin Griebel Backflow valve assembly
JP2021524756A (ja) * 2018-05-14 2021-09-16 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なサイトカインポリペプチド及びその使用方法
JP2022502088A (ja) * 2018-09-27 2022-01-11 エクシリオ デベロップメント， インコーポレイテッド マスクされたサイトカインポリペプチド
EP4034551A1 (en) * 2019-09-28 2022-08-03 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs

Also Published As

Publication number Publication date
MX2022014411A (es) 2023-01-24
WO2021236676A1 (en) 2021-11-25
US20240043488A1 (en) 2024-02-08
AU2021276337A1 (en) 2022-12-22
IL298295A (en) 2023-01-01
CN116096738A (zh) 2023-05-09
KR20230012564A (ko) 2023-01-26
EP4153612A1 (en) 2023-03-29
JP2023526428A (ja) 2023-06-21
CA3178657A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
BR112022023288A2 (pt) Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
PH12020550258A1 (en) Trispecific proteins and methods of use
CY1117401T1 (el) Πρωτεϊνες συντηξης αλβουμινης
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
AU2018298422A1 (en) Novel nucleic acid molecules
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
CY1119233T1 (el) Προϊοντα γονιδιων εκφραζομενα διαφορικα μεσα σε ογκους και εφαρμογη αυτων
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
CY1114265T1 (el) Πρωτεϊνη συντηξης αλβουμινης
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
MX9202875A (es) Una molecula de dna recombinante y procedimiento para su obtencion.
BR112017003406A2 (pt) genoma de chromobacterium subtsugae
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
BR112022006842A2 (pt) Construtos de igf2 variante
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
CO2023000048A2 (es) Conjugados de citoquina
WO2022256498A9 (en) Msln targeting trispecific proteins and methods of use